ERBB2 and breast cancer: Thus, our data confirm previous studies that HER2-positive (HR-negative) and TNBC subtypes of breast cancer are more sensitive to paclitaxel and anthracycline-based neoadjuvant chemotherapy than HER2-positive (HR-positive) and Luminal (A/B) subtypes of breast cancer.